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ABSTRACT
Purpose: A new amblyopia tracker app has been designed to provide parents with a 
method of monitoring a child’s vision by presenting a single optotype size that the 
tester moves to identify the furthest distance the optotypes can be seen. The aim of 
this study is to evaluate this methodology in adults, comparing the findings to visual 
acuity (VA) measured with the iSight app and to determine the test retest variability. 
Methods: Adults, aged 18–39 years, with no known eye condition and VA ≤ 0.7 
logMAR were recruited. Bangerter filters were used to simulate amblyopia, where VA 
was reduced below 0.0 with an interocular difference of at least 0.2 logMAR. Testing 
for both apps was performed monocularly, with the test order being randomised. 
Results: Data from 32 subjects were analysed. For the test retest variability analysis, 
paired t-tests showed no statistically significant difference between the tests for either 
eye, either app or the interocular acuity difference (p > 0.3 in all cases). Bland Altman 
plots showed similar limits of agreement between the two apps. When comparing 
measurements between the apps there was no statistically significant difference on the 
first or second test, either eye or the interocular acuity difference (p > 0.5 in all cases). 
Conclusion: The results support the theory that changing distance is a valid method of 
assessing VA as the measurements agree well with the standard approach of reducing 
optotype size. Test retest variability is similar between the two apps and there is good 
agreement between the measurements.
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INTRODUCTION
Amblyopia affects the eyesight of 2–3% of children in 
the UK and Europe (Fu et al. 2020; Hashemi et al. 2018), 
requiring home treatment with occlusion or atropine 
and careful, regular monitoring of the child’s visual 
acuity (VA). Children undergoing amblyopia treatment 
require serial measurements of their VA to monitor any 
changes in response to treatment, which means that 
patients must attend for regular eye clinic appointments 
to monitor changes. During the COVID-19 pandemic 
these regular hospital appointments were postponed for 
many months, with guidance from the British and Irish 
Orthoptic Society to reduce occlusion time due to the 
lack of formal remote monitoring tools. 
There are numerous apps available to assess VA, 
which are widely accessible, with some orthoptists 
recommending the use of apps for remote testing during 
the pandemic (Rowe et al. 2020). But the current guidance 
from the Royal College of Ophthalmologists in relation to 
paediatric ophthalmology (published 18 November 2020) 
states that ‘visual acuity apps do exist …, but they are 
not fully validated against standard visual acuity tests’ 
(Royal College of Ophthalmologists 2020). The American 
Academy of Ophthalmology guidance states that ‘online 
vision testing should be limited to healthy adults (ages 18–
39 years)’ (American Academy of Ophthalmology 2020). 
This guidance is based on the lack of evidence in relation 
to assessing VA in children. VA measurements using letter-
based apps have demonstrated good agreement with 
standard clinical tests (Ansell et al. 2020; Bastawrous et 
al. 2015). There are apps to assess VA in children, but they 
are designed for use as a screening device used by trained 
clinicians using the tumbling E optotype (Di Foggia et al. 
2020; Zhao et al. 2019). Recent reviews have identified 
a lack of validation of tests specifically for home use 
for virtual consultation telemedicine (Nagra et al. 2020; 
Steren et al. 2021). 
The Amblyopia Tracker app (Kay Pictures Ltd, 
Tring, UK) has been developed as a way for parents to 
monitor changes in a child’s vision at home while they 
are being treated for amblyopia using letter or picture 
optotypes, rather than providing a measure of visual 
acuity. The intention being that it is provided to parents 
as a monitoring tool to give clinicians and parents useful 
feedback on their child’s amblyopia progress between 
clinical appointments. It aims to minimise the issues 
associated with the home use of professional eye charts 
by measuring and recording any changes in vision in a 
different way, so that parents can see vision changes and 
improvements in a simple chart, rather than looking for 
direct VA comparisons to clinical measures that may not 
be fully understood. To perform the test, parents hold the 
phone and follow the instructions given on the phone, so 
the child only needs to respond to what they see. Results 
are provided as the furthest distance the optotype can be 
seen, and repeated tests are summarised in chart format 
to allow parents to see any changes over time. Also, the 
app will base the starting point of the test on the previous 
measurement to reduce the time to complete it.
Using an app regularly at home to monitor changes 
in vision in children with amblyopia has the potential to 
allow the eye professional treating patients to, when 
appropriate, safely lengthen the time interval between 
hospital appointments by reviewing the app results. This 
is important to avoid vision loss during the immediate 
COVID-19 pandemic and has the ongoing potential for 
significant National Health Service (NHS) savings from 
fewer hospital appointments being required. In addition, 
it is known that parent and patient understanding of 
their condition and interaction with progress improves 
compliance with amblyopia treatment (Vagge & Nelson 
2017). Providing parents a way to monitor changes and 
possible improvements in their child’s visual condition in 
a chart could have a positive effect on compliance with 
treatment.
The Amblyopia Tracker app uses the principle of 
calculating VA based on the angle subtended at the eye 
with changing distance, rather than changing optotype 
size. Theoretically, there should be no difference between 
measurements taken by changing the optotype size or 
changing the test distance with a known size of optotype, 
but no evidence was found to validate this alternative 
method of vision assessment. There are, however, a few 
studies that have measured vision at different distances 
with a standard chart. One report found no significant 
difference in visual acuity measurements taken at 3 or 
6 metres (Geddes et al. 1966). Four studies suggest that 
test distances at less than 2 metres tend to underestimate 
visual acuity; however, all these studies were on adults with 
age-related macular degeneration who had significantly 
reduced vision (Dong et al. 2002). Therefore, there is a 
need for validation that the theory works in practise and 
the test process is repeatable and reliable. 
This study is the first phase in the evaluation of 
the Amblyopia Tracker app. As the app is designed to 
monitor changes in vision, the most important measure 
of accuracy is the test-retest variability; therefore, this is 
the primary outcome of this study. In addition, variability 
results are compared with results from the iSight app 
(Kay Pictures Ltd, Tring, UK) on adults. Testing was 
completed with Bangerter filters to simulate amblyopia 
and repeated to enable the test-retest variability to be 
calculated.
METHODS
Data were collected at Manchester Royal Eye Hospital 
during a two-week period in October 2020. The study 
conformed to the principles of the Declaration of 
Helsinki, and ethical approval was obtained from the NHS 
research ethics committee, with all participants providing 
informed consent. 
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Inclusion criteria were subject age 18–39 years, 
working at the hospital, with no known eye condition, 
wearing their habitual correction. As there was a screen 
size limit of the iPhone used for the iSight Pro app, VA 
had to be better than or equal to 0.7 logMAR. Adults 
were tested to avoid the impact of cognitive ability on 
the results, and the age limits were used to prevent the 
potential impact of presbyopia when bringing the phone 
closer to the subject. The same researcher, smartphone 
(iPhone 6), room, and lighting conditions were used to 
ensure standardisation. There were three phases to the 
data collection process: initial vision testing, screening 
phase to determine the appropriate Bangerter filter to 
sufficiently reduce VA, and the testing phase. 
VISION TESTING
Both the standard visual acuity test (using Kay iSight 
Pro) and the Amblyopia Tracker were presented on 
an iPhone using a single ETDRS letter optotype in an 
optimal crowding box. For the tracker measurement, a 
fixed optotype size is presented at various test distances 
governed by a simple staircase in the app and a score 
system where three out of five correct is a pass at any size. 
The test requires users to measure their test distances 
to a maximum of 300 centimetres, which equates to a 
visual acuity score of 0.0 logMAR. The iSight app used the 
same six ETDRS letters, which matched the tracker app 
optotypes.
The fixed optotype size for the tracker app was chosen 
as the most appropriate to be used on any smartphone 
without being too small for accurate, clear display. 
However, this size does limit the best achievable score 
to 0.0 logMAR at 300 cm. As many participants had VA 
better than 0.0, Bangerter filters were introduced to 
bring acuities within the app’s range and to simulate 
amblyopia. In addition to the comparison test, test-
retest variability was determined for both test processes 
by repeated testing of each eye with each test. All testing 
was completed within one session. 
INITIAL VISION TESTING AND SCREENING 
PHASE
An initial monocular threshold vision with habitual 
correction was performed using the iSight app to inform 
whether Bangerter filters were required for the testing 
phase and to guide which filters to start with. While 
the Amblyopia Tracker app distances equate to VA 
from 0.0 to 1.3 logMAR, the iPhone could only display 
a maximum of 0.7 logMAR; therefore, vision had to be 
within a testing range of 0.0 and 0.7 logMAR. Therefore, 
the screening phase was used to ensure vision was 
within the appropriate range to enable recording 
on both apps using Bangerter filters. This was not a 
complete threshold measure as it was simply a basis to 
ensure the appropriate filters were selected to simulate 
amblyopia. An interocular acuity difference of at least 
two logMAR lines was required. When appropriate, this 
was achieved with a Bangerter filter bar using filters 
ranging between <0.1 and 1.0 to blur each participant’s 
vision appropriately. The participant was asked to hold 
the bar with a filter over one eye while the other eye 
was occluded. The iSight pro app displayed one crowded 
letter at each logMAR acuity size, descending from 0.7 
logMAR, the line with the last correct letter was recorded 
as the screening vision. 
Some participants achieved vision within the required 
range in screening but then went on to achieve better 
than 0.0 logMAR in the testing phase. As <0.0 logMAR is 
outside the testing range of the Tracker app, the decision 
was made to ensure the filters blurred participants to at 
least 0.2 logMAR in the better eye in the screening phase 
to account for any improvement in vision during the 
testing phase. 
TESTING PHASE
Monocular vision was tested with the iSight Pro and 
Amblyopia Tracker app. The order of testing was 
randomised along with which eye was tested first. Each 
app test was repeated to assess test-retest variability. 
Each participant had their vision tested a total of four 
times in each eye. 
PROCESS FOR ISIGHT PRO APP
The participant occluded the eye not being tested and 
was instructed to hold the chosen Bangerter filter in front 
of the eye being tested. Each participant was instructed 
to read aloud each letter displayed on the screen and 
to inform the investigators if they were unable to see it. 
Participants’ threshold visual acuity was assessed with 
their habitual correction. VA was measured monocularly, 
and the app was set to display one single-crowded letter 
at a time. The following protocol was used to determine 
the threshold VA:
1. Starting at 0.7 logMAR, test one letter per line until 
participant gets one wrong;
2. When one letter was incorrectly identified, return to 
the line above and test 4 more letters on this line;
3. If at least 3/5 correct, continue to next size down 
again;
4. Test 5 letters on each line until less than 3/5 correctly 
identified;
5. If less than 3/5 correct, stop testing and record VA 
based on the number of letters that were correctly 
identified on this line;
6. If 0/5 correct, record VA based on the number of 
letters that were correctly identified on the line 
before.
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PROCESS FOR THE AMBLYOPIA 
TRACKER APP
The participant occluded the eye not being tested and 
was instructed to hold the chosen Bangerter filter over 
the eye being tested. A 3 m tape measure was fixed to 
the floor, beginning beneath the participant’s seat. 
1. App displays the distance from the participant that 
the tester should hold the phone, (range 15–300 cm) 
starting at 30 cm distance.
2. Investigator taps ‘ready’ to display the first letter.
3. Investigator taps ‘correct’ or ‘incorrect’ depending on 
the participant’s answer.
4. Each participant is tested with up to five letters at 
any one distance, as specified by the app.
5. Depending on whether three out of five letters are 
correctly identified or not, the app instructs the 
researcher to move to a new, specified distance along 
the logarithmic scale between 15 cm and 300 cm. 
Step sizes are automated with a three up, one 
down process employed to identify the approximate 
distance at which the optotype is seen, followed by 
single step sizes to determine the threshold.
6. Repeat steps 1–4 until the app displays the final 
distance score to be recorded. 
Fixed step sizes were calculated following a staircase to 
minimise the number of steps needed to reach the final 
distance measurement. If the first optotype was correctly 
identified, the distance was increased by three step sizes 
(one step size equating to one logMAR line change); this 
continued until an incorrect response was given. Then 
the tester was instructed to bring the phone forward one 
step size at a time until the subject could identify three 
out of five optotypes correctly. 
STATISTICAL ANALYSIS
Tracker distances were converted to logMAR values for 
analysis. The iSight app VA scores were rounded to the 
nearest line (where a minimum of three out of five optotypes 
per line were correctly identified). Data were analysed 
using the Kolmogorov Smirnov test for normality. Only the 
second test of the left eye on the Amblyopia Tracker app 
was not normally distributed; therefore, parametric tests 
were used. To analyse the test-retest data, paired t-tests 
were used and Bland Altman plots were used to evaluate 
the agreement between tests. For the test-retest variability 
analysis, the mean bias was calculated as the first test VA 
minus the second test VA, and for the comparison between 
tests, the Amblyopia tracker app VA was subtracted from 
the iSight VA. Limits of agreement were calculated as 1.96 
times the standard deviation of the difference between 
the two tests. The sample size was determined using the 
Altman nomogram. To detect a difference of 0.1 logMAR 
(chosen to reflect a clinically significant difference) and 
a standard deviation of 0.1 logMAR based on previously 
published data using the Kay pictures book (O’Connor & 
Milling 2020), a sample size of 30 was required.
RESULTS
Thirty-six adults participated, mean age 29 years (SD 
5.4). Four were excluded from the analysis as their VA 
on the iSight app was better than 0.0 logMAR, despite 
VA worse than 0.0 logMAR during the screening phase, 
leaving 32 participants in the analysis.
TEST-RETEST VARIABILITY
Baseline VA using the iSight app without the Bangerter 
filters was RE −0.088(±0.151) and LE −0.089(±0.170) 
logMAR. One participant required no filters as their VA 
was within the required limits for the tracker app; four 
others only required a filter for one eye. 
As shown in Table 1, there is no statistically significant 
difference between test one and two for either measure 
of VA. The mean bias and limits of agreement were very 
similar across all tests, with a mean bias close to zero for 
both VA tests on first and second test. Figure 1 is a Bland 
Altman plot showing the agreement between test one 
and two of the right eye for the Amblyopia Tracker app.
VA ISIGHT APP (LOGMAR) MEAN ± SD TRACKER APP LOGMAR VALUE MEAN ± SD
RE LE RE LE
Test 1 0.44 ± 0.204 0.38 ± 0.201 0.43 ± 0.214 0.39 ± 0.20
Test 2 0.42 ± 0.219 0.38 ± 0.214 0.44 ± 0.238 0.38 ± 0.23
Paired t-test p value 0.34 1.0 0.66 0.39
Mean bias ± SD 0.02 ± 0.126 0 ± 0.114 –0.01 ± 0.120 0.02 ± 0.120
Upper LoA 0.269 0.222 0.226 0.255
Lower LoA –0.226 –0.222 –0.245 –0.217
Table 1 VA data for each eye and each test from the iSight and Amblyopia Tracker apps, mean bias, and upper and lower limits of 
agreement (LoA).
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As there are overlapping data points on the Bland 
Altman plot, Figure 2 shows the numbers of subjects 
for each line of difference between the first and 
second test. The proportions of subjects with one or no 
lines difference between the first and second test on 
the iSight test was 84% for the right eye and 88% for 
the left eye. For the tracker app it was 81% for each 
eye. 
As the aim of the tracker app is to monitor VA in patients 
with amblyopia, it is important to analyse the interocular 
acuity difference data in combination with the monocular 
VA scores. Paired t-test analysis showed no statistically 
significant difference in the IAD for either method on 
either test (iSight app p = 0.5, tracker app p = 0.4). 
COMPARISON BETWEEN TESTS
Table 2 shows the VA results are very similar between 
tests with a mean bias close to zero, as shown in Figure 3, 
and no statistically significant difference found.
When comparing the IAD between the tests there was 
no statistically significant difference on test one or two 
(see Table 3).
Figure 1 Bland Altman showing agreement between test one and test two of the right eye for the tracker app, comparing the mean 
of the two tests against the difference.
Figure 2 Bar chart showing the numbers of participants and the difference in VA between test one and two for each eye and each test.
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DISCUSSION
This first phase of evaluation of the new Amblyopia 
Tracker app was designed to determine if the concept 
of changing the test distance rather than optotype 
size produces equivalent VA responses to the standard 
test method. The results support the theory behind the 
change in approach to assessing VA and demonstrate 
that when clinicians use the tests on cooperative adult 
subjects, test-retest variability is equivalent to the iSight 
app and there is good agreement between the tests. 
While there is no statistically significant difference 
when comparing test one and two and methods, there is 
some variability. A degree of variability is expected, with 
previous data showing that when assessing VA using the 
HOTV test, 93% (n = 163) of responses had either one line 
or no difference on retest (Holmes et al. 2001) and the 
same finding of 93% (n = 42) for Lea symbols (Chen et al. 
2006). One app, designed for children with a C optotype 
presented in a game format at near, is reported to have 
limits of agreement of ±0.208 (Aslam et al. 2016). The 
findings from the current study showed slightly greater 
variability (81% with either one line or no difference on 
retest). This may be due to the smaller sample size or 
because vision loss was simulated rather than testing 
people with an existing vision problem. However, reports 
ISIGHT IAD TRACKER APP IAD
TEST 1 TEST 2 DIFFERENCE TEST ONE TEST TWO DIFFERENCE 
0.056 ± 0.350 0.034 ± 0.378 0.022 ± 0.181 0.034 ± 0.357 0.063 ± 0.390 –0.028 ± 0.195
Table 3 Interocular acuity difference (mean ± SD) for the iSight app and tracker app.
VA ISIGHT APP (LOGMAR) – VA TRACKER APP
RE TEST 1 RE TEST 2 LE TEST 1 LE TEST 2
Mean bias±SD 0.013 ± 0.131 –0.019 ± 0.164 –0.009 ± 0.106 0.009 ± 0.112
Upper LoA 0.270 0.302 0.198 0.228
Lower LoA –0.245 –0.339 –0.217 –0.210
Paired t-test p value 0.59 0.52 0.62 0.64
Table 2 Comparison of the VA results between the two testing methods.
Figure 3 Bland Altman plot of the right eye data comparing responses between the two test methods.
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of test-retest variability using the ETDRS chart show 
considerable variation, with studies defining a change 
needing to be greater than one (Rosser et al. 2003) or 
two (Rosser et al. 2001) lines difference to identify a 
significant change. Results from this study agree as there 
was a maximum of two participants (6%) above two 
lines difference on any test. 
Sources of potential variability were controlled where 
possible by keeping conditions standardised and limiting 
the number of testers, but the use of Bangerter filters 
introduced a degree of variability. It is known that the 
VA measured through the filters does not correspond 
well with their labelled density designation (Odell et al. 
2008; Perez et al. 2010), but this was controlled for by 
implementing a screening phase to select a filter that 
ensured the VA through the filter was within the testing 
range. During testing, subjects reported that the filters 
were not homogenous, with vision varying depending on 
where they were looking through the filter. To minimise 
this impact, subjects were monitored and asked to 
keep their head still when movement was seen and 
to hold the filter against their face to minimise any 
movement. While the impact was minimised, there was 
a degree of variability attributable to the use of these 
filters.
The decision to compare the Amblyopia Tracker app 
to the iSight app was to eliminate any impact of the 
presentation of the optotype on acuity, as slight (but not 
statistically significant) differences have been reported 
between clinical charts and VA tests presented on digital 
devices (Ansell et al. 2020; Bastawrous et al. 2015). 
The ETDRS chart is considered to be the gold standard 
for clinical care, with studies typically comparing the 
results to this test. However, the decision was made 
to compare to another app (using ETDRS letters) as 
the app is designed to be a standalone device utilised 
to detect change, where the aim of this study was to 
determine if the method of changing distance rather 
than optotype size was valid. Therefore, rather than 
adding another test and introducing potential fatigue 
effects, comparison with the ETDRS test was not 
included.
This initial phase provides a proof of concept, but the 
aim of the app is for it to be used by parents/guardians in 
the home environment to allow them to track changes in 
VA. The app tutorial does explain the need to ensure test 
distances are accurate, but it is anticipated that children 
would be more likely to move during testing than the 
adults in this study, increasing the variability in test 
distance. When testing VA at 40 cm, a reduction of 8 cm 
would be required to improve vision by one line, but with 
increasing test distances much larger movements would 
need to be made to result in an impact on VA (Tidbury & 
O’Connor 2015). At 40 cm, the fixed size optotype on the 
Amblyopia Tracker app is approximately equal to a VA of 
0.9 logMAR, so additional caution may be required when 
testing children with VA at this level. 
The data presented here are from the first phase 
evaluating the Amblyopia Tracker app. This is an important 
step given that assessment at home introduces more 
sources of variability. During the COVID-19 pandemic, 
the use of apps to assess VA at home was evaluated, but 
one study had a very low participation rate (only 16% of 
parents that gave consent to participate provided data) 
(Painter et al. 2021), and another reported a modest 
correlation with clinical tests (Silverstein et al. 2021). 
Therefore, further evaluation of the Amblyopia Tracker 
app is underway, with parents testing children at home 
and then testing repeated on return to the clinic. Parental 
views, via an online questionnaire, are being sought in 
relation to usability in addition to measuring the test-
retest variability. 
CONCLUSION
Changing the method of measuring the threshold VA 
from altering optotype size to changing the test distance 
produces comparable results. Results are comparable 
between the Amblyopia Tracker app and the iSight app, 
with no difference in monocular VA’s or the interocular 
acuity difference and similar test-retest variability. The 
new Amblyopia Tracker app is designed to provide a 
simplified method of monitoring vision between hospital 
visits, so further evaluation is currently in progress to 
address this.
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